Keynote
What happens when replacement parts for the human body become real, and they are grown from your own cells? Drawing on the first human trials of lab-grown bone, Nina charts the path from one-size-fits-all healthcare to treatments as personal as a fingerprint, and from living longer to living fully: lifespan, healthspan, and what she calls joyspan.
Longevity science is moving from supplements and speculation to surgery and clinical trials. Nina leads the company that put the first stem-cell grown living bone into human beings, so when she talks about replacement parts for the human body, she is describing her own pipeline. From bone and cartilage today to more complex tissues tomorrow, she walks audiences through what regenerative medicine can genuinely deliver, on what timeline, and at what cost.
Over a million people saw Nina ask a question on the TED stage: could tissue engineering mean personalized medicine? A decade later, her company answers it in the operating room, growing anatomically precise bone from each patient's own stem cells, so the graft is as personal as a fingerprint. The talk traces that arc from idea to implant and tours the personalization frontier: patient-derived tissues, organs-on-chips replacing animal trials, and care that starts from your own cells.
Then she asks the question that matters to everyone in the room: longer for what? Lifespan counts the years. Healthspan counts the years in good health. Joyspan, Nina's term, counts the years you can still do what you love, and skeletal health decides much of it. When a seventy-year-old knee can be regrown and an injury at fifteen stops dictating the rest of a life, entire industries reorganize: how we work, insure, invest, and plan. Nina brings a founder's pragmatism and an engineer's honesty, along with the operational questions of regulation, reimbursement, and readiness that decide who benefits first.
Watch
More keynotes
AI is learning the language of cells. Nina maps the convergence of machine intelligence and living systems — from algorithm-designed tissues to biology as the next computing platform — and what it means for every industry that touches the human body.
For
Cells are becoming partners in design: self-healing bridges, living textiles, lab-grown bone and meat. Nina shows how growing products will transform materials, medicine, and supply chains, and what it takes to grow living products safely and at home: the biomanufacturing capacity, the safeguards, and the policy choices behind a secure bioeconomy.
For
Living bone grown from a patient's own cells was science fiction a decade ago. Today it is in human trials. Nina shares what it took to get there, from lab bench to FDA-cleared clinical trials: building teams, culture, and conviction for a product that is alive, and the lessons that transfer to anyone building something the world calls impossible.
For
Patients research, organize, invest, and demand better. Drawing on a decade of getting EpiBone's first patient to the operating room and the emails that kept arriving, Nina charts how people in pain became partners in medicine: as advocates, as investors through crowdfunding, and as participants claiming the right to try.
For
From TED to Davos, Nina translates the frontier of biology and technology into talks audiences never forget.
Keynotes are booked through The Lavin Agency. Interviews, podcasts, and campus or community talks come straight to Nina's team.